Central Nervous System Collaboration And Licensing Agreements Benchmark Report 2026: Structured Analysis Of 900+ Deals Signed Since 2020 - Financial Terms, Upfronts, Milestones, And Royalties

(MENAFN- GlobeNewsWire - Nasdaq) This report provides a comprehensive and structured analysis of 900+ CNS collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Central Nervous System Collaboration and Licensing Deals 2020-2026" report has been added to ResearchAndMarkets's offering.
The definitive benchmark for central nervous system dealmaking
Central nervous system (CNS) partnering spans a wide range of deal structures across indications, modalities, and stages of development, reflecting the scientific complexity and risk profile of the space.
This report provides a comprehensive and structured analysis of 900+ CNS collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
The report enables a precise understanding of how CNS deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly heterogeneous therapeutic landscape
• Full visibility into deal structure and execution

Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.
This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections

This level of transparency is critical to understanding how value, risk, and control are allocated within CNS partnerships, particularly in areas with higher development uncertainty.
Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data

What's included?

• 900+ CNS collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for CNS dealmaking

Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how CNS partnerships are structured, negotiated, and valued.
Key Topics Covered:
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking
2.1. Introduction
2.2. Central nervous system partnering over the years
2.3. Central nervous system partnering by deal type
2.4. Central nervous system partnering by industry sector
2.5. Central nervous system partnering by stage of development
2.6. Central nervous system partnering by technology type
2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering
3.1. Introduction
3.2. Disclosed financials terms for central nervous system partnering
3.3. Central nervous system partnering headline values
3.4. Central nervous system deal upfront payments
3.5. Central nervous system deal milestone payments
3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers
4.1. Introduction
4.2. Most active in central nervous system partnering
4.3. List of most active dealmakers in central nervous system
4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory
5.1. Introduction
5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by central nervous system therapeutic target

Deal Directory

• Deal Directory - Central nervous system deals by company A-Z
• Deal Directory - Central nervous system deals by technology type
• Deal type definitions

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19052026004107003653ID1111135732